As Trial Nears, Kaiser Flays Pfizer Neurontin Studies

By Samuel Howard

Law360, New York (January 21, 2010, 7:04 PM ET) -- With a trial in the multidistrict litigation over Pfizer Inc.’s alleged off-label marketing of Neurontin just a month away, Kaiser Foundation Health Plan Inc. is attacking the credibility of Pfizer’s expert testimony, contending the doctors embraced sham clinical results when vouching for the drug’s effectiveness as a treatment for bipolar disorder and migraines.

Kaiser urged Judge Patti B. Saris of the U.S. District Court for the District of Massachusetts on Thursday to reject five of Pfizer’s experts, saying they suppressed negative results and relied on inferior,...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles